

A study to evaluate the efficacy and tolerability of atenolol and amolodopine with atenolol in maintaining normal blood pressure

Sameer Kumar¹, Neetu Sahay², Pankaj Kumar Singh³

¹Associate Professor, Department of Pharmacology, Vardhman Institute of Medical sciences, Pawapuri, Nalanda, Bihar, India

²Tutor, Department of PSM, Vardhman Institute of Medical Sciences, Pawapuri, Nalanda, Bihar, India

³Tutor, Department of Pharmacology, Vardhman Institute of Medical sciences, Pawapuri, Nalanda, Bihar, India

Received: 14-05-2021 / Revised: 01-07-2021 / Accepted: 04-08-2021

Abstract

Background: Hypertension is one of the most common non-communicable disease. There are a number factors, presently prevalent in our daily life that are increasing the prevalence of hypertension in nearly all age groups, but more as age increases. **Aim:** The present study was undertaken to determine the difference between efficacy and tolerability of atenolol and combination of amolodopine and atenolol in maintaining normal blood pressure. **Materials and method:** A total of hundred patients were taken for the study. Fifty patients are given atenolol and other fifty are given combination of amolodopine and atenolol, once a day, daily for one month. Blood pressure of all the patients is recorded daily in laying position for one month. Data collected was analyzed statistically using descriptive statistics. Any adverse effects, symptoms of hypertension and patient compliance is also noted in the follow up visits. **Results:** Blood pressure levels were maintained at normal limits, more in combination therapy compared to atenolol alone therapy. Blood pressure variations were also less with combination therapy. Side effects were somewhat more in the combination therapy. Patient compliance was good. **Conclusion:** Combination of amolodopine and atenolol seems to be more effective in the treatment of hypertension in comparison to atenolol alone.

Keywords: Atenolol, Amolodopine, Hypertension.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Hypertension is one of the most common non-communicable disease. There are a number factors, presently prevalent in our daily life that are increasing the prevalence of hypertension in nearly all age groups, but more as age increases. Beta receptor antagonists are one of the groups of drugs used in all grades of hypertension. Ca²⁺ channel blockers are the other class of antihypertensive agents, used in different situations of hypertension. But many times, single drug therapy is not sufficient to maintain normal blood pressure. And combination therapy has its own problems like increase side effects, cost etc. Hence, present study is undertaken to determine the difference between efficacy and tolerability of atenolol and combination of amolodopine and atenolol. Hypertension, increase in blood pressure, is one of the most common clinical condition seen in day-to-day life. Hypertension is responsible for 6% of deaths worldwide. Long term constant increase in blood pressure increases the risk of coronary artery disease, congestive heart failure, ischemic and hemorrhagic stroke, renal failure, and peripheral arterial disease. Blood pressure variability, other than normally occurring in physiological conditions, is associated with premature death and cardiovascular events. So the blood pressure is maintained within normal limits by using different groups of antihypertensive drugs, singly or in combination to prevent the complications of hypertension. [3,22,18]. They are mainly two ways of treatment of hypertension, Nonpharmacological therapy and

Pharmacological therapy. Nonpharmacological therapy is the lifestyle modifications like aerobic exercise, weight loss (in overweight individuals), restricting sodium intake, decreasing stress and avoiding smoking and alcohol. Nonpharmacological therapy is applied to all the patients of hypertension, in all stages, with or without pharmacological therapy. Many of the elevated hypertensive patients and in some of the stage I hypertensive patients, nonpharmacological therapy is sufficient. [4] Pharmacological therapy includes use of various antihypertensive drugs, as monotherapy or in combination to maintain the normal blood pressure. There are different groups of antihypertensive drugs of different mechanisms of action like: Diuretics, ACE Inhibitors, Angiotensin receptors blockers, Calcium channel blockers, β Adrenergic blockers, α Adrenergic blockers, $\alpha+\beta$ Adrenergic blockers, Central sympatholytics, Vasodilators etc. Different types of drugs are tried in different stages of hypertension in different age related or comorbid conditions. [20] But many times, single drug therapy is not sufficient to maintain normal blood pressure. And combination therapy has its own problems like increase side effects, cost etc. Hence, present study is undertaken to determine the difference between efficacy and tolerability of atenolol and combination of amolodopine and atenolol.

Materials and Methods

This prospective, cross sectional, unicentric, observational study was conducted at Vardhman Institute of Medical Sciences, Pawapuri, Nalanda, Bihar. The study was approved over a period of 1 year time from May 2020 to April 2021. The study was approved by the institutional research and ethical committee. An informed and written consent was taken from all the participating subjects prior to the commencement of the study.

The study sample consisted of the OPD patients reporting to the General Medicine OPD of our Institutional Hospital. The subjects

*Correspondence

Dr. Pankaj Kumar Singh

Tutor, Department of pharmacology, Vardhman Institute of medical sciences, Pawapuri, Nalanda, Bihar, India

E-mail: pankaj Singh0536@gmail.com

were selected randomly by random convenient sampling. Subjects who consented to participate in the study were included in the study. Subjects with comorbidity were excluded from the study. A total of one hundred patients participated for the study. Fifty patients are given atenolol and other fifty are given combination of amlodipine and atenolol, once a day, daily for one month. Blood pressure of all the patients is recorded daily in laying position for one month. Data collected was analyzed statistically using descriptive statistics. Any adverse effects, symptoms of hypertension and patient compliance is also noted in the follow up visits. The objective parameters i.e recording of blood pressure is done daily for one month, patient is first asked to relax for 10 minutes and blood pressure is recorded in

laying position. Patients are also asked about daily intake of medicine, any adverse effects or any symptoms of hypertension.

Results and Discussion

This is an observational study in which the efficacy and tolerability of atenolol and that of combination of Amlodipine and Atenolol in the treatment of hypertension is compared. Subjects are either are given atenolol 50mg tablet once daily or a combination of amlodipine 5mg and atenolol 50mg tablet single dose daily. According to McGill JB et al, once daily betablockers have good patients compliance in mild to moderate hypertension. According to Barrett J, et al, increasing the dose of amlodipine dose from 5mg to 10mg notably decreases blood pressure in older patients. [7, 25, 12] Table 1 shows the age distribution of the patients.

Table 1: shows age of the patients

Age group	Total number of patients	Number of patients with atenolol treatment	Number of patients with combination therapy
0-18	0	0	0
19-60	70	32	38
>60	30	18	12
Total	100	50	50

Most of the patients are in the age group of 19 to 60 years (70%). 30% of the patients are above 60 years.

Table 2: shows blood pressure of the patients on different days of the study.

Visits	Atenolol treatment		Stage 1 Hypertension		Stage 2 Hypertension		Combination therapy		Stage 1 Hypertension		Stage 2 Hypertension	
	Normal BP	Elevated BP			Normal BP	Elevated BP						
Day 1	4	8	27	11	4	7	30	9				
Day 5	6	24	16	4	30	14	6	0				
Day 10	10	18	20	2	36	10	4	0				
Day 15	10	20	19	1	42	8	0	0				
Day 20	16	19	15	0	46	4	0	0				
Day 25	24	18	8	0	48	2	0	0				
Day 30	40	10	0	0	48	2	0	0				

Table 2 shows blood pressure of all patients noted at different days of the study. Baseline blood pressure readings of all patients is taken on day 1. On day 5, 11 patients had stage 2 hypertension in atenolol treatment group of patients and 9 patients in combination therapy group. At day 10, 20 patients on atenolol treatment and only 4 patients on combination therapy had stage 1 hypertension. At day 20, 19 patients on atenolol treatment and 4 patients on combination therapy had elevated blood pressure. At the end of the study i.e on the day 30, 40 patients shown normal blood pressure in atenolol group as compared to 48 patients in combination therapy group. There was a gradual decrease in the blood pressure levels as the study progressed in all patients, but more faster decline in blood pressure is seen in combination therapy group of patients than in atenolol alone treatment. At the end of the study, most of the patients were maintaining normal blood pressure level with their respective treatments. β blockers are one of the main group of drugs used in hypertension. β blockers acts by antagonism of adrenergic receptors that causes reduction in myocardial contractility, heart rate, and cardiac output leading to fall in blood pressure. β blockers decreases the production of circulating Angiotensin II by acting on adrenergic receptors of the juxtaglomerular complex of kidney. β blockers are mild antihypertensive drugs and their effects last for 24 hour with single dose. According to Aursnes I, et al, atenolol caused decrease in heart rate is associated with increased cardiovascular events and stroke in hypertensive patients. Atenolol is associated with glucose intolerance particularly in diabetics, that's why it is not use as first line drug in hypertensive patients. According to Ibrahim MM, et al, Even better other β blockers are also available like metropolol than atenolol. Low-dose thiazides diuretics are preferred first-line drugs, next is calcium channel blockers and next to calcium channel blockers are β blockers. According to Morgan TO, et al, atenolol is not preferred as reference drug, sounds logical as compared to this study. [20, 19, 31, 17, 30, 36, 6, 35, 23, 37, 11, 9, 21, 28, 24]

Calcium channel blockers causes fall in blood pressure by inhibition of calcium influx in vascular smooth muscles leading to vasodilatation. The difference in different calcium channel blockers in the selectivity for arterial, venous or heart muscles cells, results in the variations in their actions that decides the choice of a particular calcium channel blocker in different hypertensive conditions. Nifedipine has less cardiac muscles effects in relation to verapamil and diltiazem. They have equal ability to prevent stroke in hypertensive patients as compare to ACE Inhibitors. According to Barrett J, et al, amlodipine has shown good response in the treatment of hypertension with diabetes or renal dysfunction patients. [1,2,37,8,10,27,33]BPV, blood pressure variations occurring in minutes, hours or days throughout in the patients, significantly effects the cardiovascular outcomes. Usually it is less with amlodipine treatment as seen in different studies, In this study, blood pressure variations is more with atenolol therapy group of patients as compared to combination therapy.[32,16,23] Combination of amlodipine and atenolol is commonly used for the control of blood pressure, not controlled by single drug therapy. Presently, maximum number of hypertensive patients are in the need of combination therapy to maintain normal blood pressure. Combining different groups of drugs has higher efficacy in reduction of blood pressure as compared to increasing the dose of single drug. According to Wald DS, et al, combination of amlodipine and atenolol have superior effect on reduction in blood pressure, blood pressure variations and end organ damage than single drug therapy. UV- spectrophotometric is used to calculate the dose of individual drug in different combinations in different studies. According to Boutouyrie P, et al, Combination of amlodipine and valsartan has greater central systolic blood pressure reduction compared to combination of amlodipine and atenolol. That means we got other better combinations of drugs than combination of amlodipine and atenolol. And certainly, combination of amlodipine and atenolol

causes more reduction of blood pressure than atenolol alone. [29, 26, 34, 13-15]

Conclusion

Blood pressure levels were maintained at normal limits, more in combination therapy compared to atenolol alone therapy. Blood pressure variations were also less with combination therapy. Side effects were somewhat more in the combination therapy. Patient compliance was good.

References

- Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical 3, 2015.
- Del Mauro JS et al. Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. *J AMSoc Hypertens.* 2017; 1(4):227-240.
- Ahlquist D, Camilleri M editors. Cardiovascular Diseases. In: Harrison's: Principles of internal medicine. 19th Ed. McGraw Hill companies, 2016, 241-250.
- Brunton LL, Chabner BA, Knollmann BC editors. Treatment of Myocardial ischemia and Hypertension. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th Ed. New York: McGraw-Hill Companies, 2017.
- Kuyper LM, Khan NA. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. *Can J Cardiol.* 2014; 30(5):S47-53.
- McGill JB. Optimal use of beta blockers in high-risk hypertension: a guide to dosing equivalence. *Vasc Health Risk Manag.* 2010; 6:363-72.
- Oparil S et al. Long term morbidity and mortality trials with amlodipine. *Journal of Cardiovascular Pharmacology.* 1999; 33:S1-S6.
- Carlberg B, Lindholm LH. Atenolol in hypertension: is it a wise choice?. *The Lancet.* 2005; 365 (9460): 656.
- Aursnes I, Tveite IF et al. Clinical efficacies of antihypertensive drugs. *Scandinavian Cardiovascular Journal.* 2003; 37:2.
- Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta blockers, calcium channel blockers and diuretics for the control of systolic hypertension. *American journal of hypertension.* 2001; 14(3):241-247.
- Frishman WH et al. Amlodipine versus atenolol in essential hypertension. *The American Journal of Cardiology.* 1994; 73(3):A50-A54.
- Ling G et al. Effects of combination therapy with at Enolol and amlodipine on blood pressure control and stroke prevention in stroke-prone spontaneously hypertensive rats. *Acta Pharmacol Sin.* 2007; 28(11):1755-60.
- Wald DS et al. Combination therapy versus monotherapy in reducing blood pressure : Meta-analysis on 11,000 participants from 42 trials. *The American Journal of Medicine.* 2009; 122(3):290-300.
- Han P et al. The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats. *J Cell Mol Med.* 2009; 13(4):726-34.
- Wang JG et al. Predictors of visit-to-visit blood pressure variability in patients with hypertension: an analysis of trials with an amlodipine treatment arm. *J AMSocHypertens.* 2017; 11(7):402-411.
- Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker induced Heart rate lowering and cardioprotection in Hypertension. *Journal of the American College of Cardiology.* 2008; 52(18):20-24.
- Kostis JB. Visit-to-visit variability of blood pressure. *JAMSoc Hypertens.* 2017; 11(8):473-474.
- Ibrahim MM, Mossallam R. Clinical evaluation of atenolol in hypertensive patients. *Circulation.* 1981; 64(2):368-74.
- Tripathi KD. Antihypertensive Drugs. In: Essentials of Medical Pharmacology. Jaypeebrothers medical publishers, 2011, 7.
- Wright JM, Musuni VM. First-line drugs for hypertension. *Cochrane Database Syst Rev,* 2009, 3.
- Wang JG et al. Effects of amlodipine and other classes of antihypertensive drugs on long term blood pressure variability: evidence from randomized controlled trials. *J AMSoc Hypertens.* 2014; 8(5):340-9.
- Rothwell PM et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. *Lancet Neurol.* 2010; 9(5):469-80.
- Wong GW et al. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. *Cochrane Database Syst Rev.* 2016; 3:CD007451.
- Barrett J, Rahul B, Jeffery R. incremental blood pressure-lowering effect of titrating amlodipine for the treatment of hypertension in patients including those aged ≥ 55 years. *American journal of therapeutics.* 2015; 22(4):278-287.
- Kasture AV, Ramteke M. Simultaneous UV- spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form. *Indaian J Pharm Sci.* 2006; 68(3):394-396.
- Barrett J, Jeffery R, Rahul B. Efficacy of calcium channel blockers versus other classes of antihypertensive medication in the treatment of hypertensive patients with previous stroke and/or coronary artery disease: A systemic review and meta-analysis. *American journal of therapeutics.* 2017; 24(1):e68-80.
- Chen N et al. Calcium channel blockers versus other classes of drugs for hypertension. *Cochrane Database Syst Rev.* 2010; 8:7-8.
- Boutouyrie P et al. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. *Hypertension.* 2010; 55(6):1314-22.
- Aursnes I, Osnes JB. Does Atenolol differ from other Beta-Adrenergic Blockers. *BMC Clinical Pharmacology.* 2007; 7:4.
- Aursnes I, Osnes JB. Atenolol versus other Beta-Adrenergic Blockers. *Journal of the American College of Cardiology.* 2009; 53(22):36-56.
- Park S et al. Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure. *J AMSocHypertens.* 2016; 10(10):799-810.
- Barrett J, Jeffery R, Rahul B. A systematic review on th efficacy of amlodipine in the treatment of patients with hypertension with concomitant diabetes mellitus and/or renal dysfunction, when compared to other classes of antihypertensive medication. *American journal of therapeutics.* 2015; 22(5):322-341.
- Gradman AH et al. Combination therapy in hypertension. *Journal of the American Society of Hypertension.* 2010; 4(2): 90-98.
- Wlysonge CS et al. Beta-Blockers for Hypertension. *Cochrane Database Syst Rev.* 8, 2012.
- Lindholm KH et al. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet.* 2005; 366(9496):1545-53.
- Oparil S et al. Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials. *Drugs.* 2000; 59:25-37.

Conflict of Interest: Nil Source of support: Nil